Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of ...
stimulating liver regeneration; and (iv) as inhibitors of the transformation of stellate hepatocytes into myofibroblasts, the process responsible for the deposition of collagen fibres leading to ...
Aug. 21, 2024 — A research team has shown the benefits of camu-camu on non-alcoholic fatty liver disease. This exotic fruit reduces liver fat ... Liver Transplant Outperforms Other Therapies for ...